Online inquiry

IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7146MR)

This product GTTS-WQ7146MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTGF gene. The antibody can be applied in Hepatic fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001901.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1490
UniProt ID P29279
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7146MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12860MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ4678MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ3748MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ15697MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ1660MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ11587MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MGAH-22
GTTS-WQ4731MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ10457MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2541546
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW